Genzyme kept at neutral by Merrill

Genzyme Corp. was maintained by Merrill Lynch analyst Eric Ende at neutral after the company reiterated its 2006 guidance on its recent analysts' day. Genzyme gave higher-than-expected Myozyme pricing while downplaying potential competition for Fabrazyme and Cerezyme. Merrill upped its earnings-per-share estimates to $2.69 from $2.66. Shares of the Cambridge, Mass., biotechnology company were up 36 cents, or 0.65%, at $55.96 on volume of 3,482,235 shares versus the three-month running average of 2,663,190 shares. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.